Bioggio, Switzerland, 31 October 2011- Telormedix, a clinical stage biopharmaceutical company focused on TLR7 agonists in the treatment of cancer and inflammatory diseases, today announced that it has achieved significant preclinical results for TMX-202, a compound developed for the safe and effective topical treatment of skin cancer.
The recent preclinical study evaluated TMX-202 as a topical skin cancer treatment in a mouse skin cancer model and showed that it had both better efficacy and better tolerability than the current gold standard treatment for skin cancer, Imiquimod/Aldara. Unlike Imiquimod, TMX-202 did not interact with adenosine receptors or other pain associated receptors (Na+ channels). TMX-202 has previously been shown to penetrate both human and pig skin, inducing inflammatory cell infiltration and topical treatment causes low systemic, pro-inflammatory cytokines when compared to Imiquimod.
Johanna Holldack, CEO of Telormedix, commented: “There is currently a strong need for the development of more effective and safe topical treatments for skin diseases. Based on these promising preclinical results, we intend to further analyse TMX-202 in order to confirm its properties in animal models best suited for studying the topical treatment of skin cancer and other skin disorders, such as actinic keratosis (AK) and genital warts.”
TMX-202 is a new chemical entity for topical treatment that optimizes skin penetration and through that delivery of the active ingredient. The molecule activates Toll-like Receptor 7 (TLR7) with high selectivity, inducing a prolonged but reversible production of cytokines in vivo. In cellular assays, TMX-202 showed 2-3 logs of enhanced potency as compared to Imiquimod, the active ingredient of Aldara.
Telormedix (www.telormedix.com), founded in October 2007, is a biopharmaceutical company focused on targeted immunity and modulation of the innate immune system for treating cancer and autoimmune diseases. The Company’s lead product, TMX-101, recently entered a Phase I/II clinical trial for the treatment of Non-Muscle Invasive Bladder Cancer (NMIBC). In addition, Telormedix is developing two TLR7-targeted molecules, TMX-201 and TMX-202, as a vaccine adjuvant. One of these molecules, TMX-202, has recently been selected for preclinical study for the topical treatment of skin cancers and other indications. The candidate has already successfully completed a number of in vivo studies.
Located in Switzerland, Telormedix is led by a highly experienced management team and backed by an international consortium of venture capitalists including Aravis Venture (Basel, Switzerland), Proquest Investments (Princeton-San Diego, USA), BSI S.A. (Lugano, Switzerland), Nextech Venture (Zurich Switzerland) and Generali Insurance Group (Italy).
t: +41 (0)91 610 7000
Senior Account Manager
College Hill Life Sciences
t : +49 (0)89 5238 8030